It is almost 20 years since NNRTIs were identified as a new class of antiretroviral drugs for
the treatment of HIV-1 infection. Although they belong to different and diverse chemical …

The non-nucleoside reverse transcriptase (RT) inhibitors (NNRTIs) are a therapeutic class of
compounds that are routinely used, in combination with other antiretroviral drugs, to treat …

Human immunodeficiency virus (HIV) reverse transcriptase (RT) inhibitors can be classified
into nucleoside and nonnucleoside RT inhibitors. Nucleoside RT inhibitors are converted to …

Background Despite the availability of effective antiretroviral therapies, drugs for HIV-1
treatment with new mode of action are still needed. An innovative approach is aimed to …

Since the human immunodeficiency virus (HIV) was discovered as the etiological agent of
acquired immunodeficiency syndrome (AIDS), it has encouraged much research into …

HIV-1 reverse transcriptase (RT) contains both DNA polymerase and RNase H activities to
convert the viral genomic RNA to dsDNA in infected host cells. Here we report the 2.65-Å …

Hundreds of structures of type 1 human immunodeficiency virus (HIV-1) reverse
transcriptase (RT) have been determined, but only one contains an RNA/DNA hybrid. Here …

Background Tenofovir disoproxil fumarate (TDF), emtricitabine (FTC), and efavirenz (EFV)
are the three components of the once-daily, single tablet regimen (Atripla) for treatment of …

Thymidine analogue-associated mutations (TAMs) in reverse transcriptase (RT) of the
human immunodeficiency virus type 1 (HIV-1) cause resistance to 3′-azido-3 …

Recently, mutations in the connection subdomain (CN) and RNase H domain of HIV-1
reverse transcriptase (RT) were observed to exhibit dual resistance to nucleoside and …